Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 3
2011 3
2012 3
2013 4
2014 3
2015 2
2016 5
2017 6
2018 4
2019 1
2020 4
2021 4
2022 2
2023 2
2024 8
2025 19
2026 7

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Results by year

Citations

1 article found by citation matching

Search results

Filters applied: . Clear all
Page 1
Pathway inhibition: emerging molecular targets for treating glioblastoma.
Wick W, Weller M, Weiler M, Batchelor T, Yung AW, Platten M. Wick W, et al. Neuro Oncol. 2011 Jun;13(6):566-79. doi: 10.1093/neuonc/nor039. Neuro Oncol. 2011. PMID: 21636705 Free PMC article. Review.
Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblastoma treatment. Recent results of bevacizumab may represent a proof of principle that treatment with targeted agents can result in …
Therefore, the identification of novel molecular targets and inhibitory agents has become a focus of research for glioblast …
Emerging therapies for glioblastoma.
Sarfraz Z, Ranjan T, Mustafayev FNA, Jaramillo M, Odia Y, Venur VA, Ahluwalia MS. Sarfraz Z, et al. J Neurooncol. 2025 Dec 10;176(1):116. doi: 10.1007/s11060-025-05248-x. J Neurooncol. 2025. PMID: 41372729 Review.
JAK/STAT inhibition, PARP blockade, and PI3K/AKT/mTOR pathway modulation remain under investigation, although clinical benefit has been inconsistent. In parallel, precision oncology platforms incorporating multi-omic profiling, patient-derived organoids, and functio …
JAK/STAT inhibition, PARP blockade, and PI3K/AKT/mTOR pathway modulation remain under investigation, although clinical benefit …
Emerging therapeutic targets for cerebral edema.
Jha RM, Raikwar SP, Mihaljevic S, Casabella AM, Catapano JS, Rani A, Desai S, Gerzanich V, Simard JM. Jha RM, et al. Expert Opin Ther Targets. 2021 Nov;25(11):917-938. doi: 10.1080/14728222.2021.2010045. Epub 2022 Jan 2. Expert Opin Ther Targets. 2021. PMID: 34844502 Free PMC article. Review.
Current treatment options are limited, reactive, and associated with significant morbidity. Targeted therapies are emerging based on a growing understanding of the molecular underpinnings of cerebral edema. AREAS COVERED: We review the pathophysiology and rel …
Current treatment options are limited, reactive, and associated with significant morbidity. Targeted therapies are emerging ba …
Status and Prospects of Glioblastoma Multiforme Treatments.
Yang X, Wang S, Montana V, Tong X, Parpura V. Yang X, et al. J Neurochem. 2025 Jul;169(7):e70158. doi: 10.1111/jnc.70158. J Neurochem. 2025. PMID: 40682424 Review.
Glioblastoma multiforme (GBM) is the most aggressive and common primary brain cancer in adults. ...In recent years, novel therapeutic approaches for the treatment of GBM have emerged: (i) tumor-treating fields delivering nonionizing low-intensity alternating …
Glioblastoma multiforme (GBM) is the most aggressive and common primary brain cancer in adults. ...In recent years, novel therapeutic …
An Insight into Emerging Phytocompounds for Glioblastoma Multiforme Therapy.
Prakash V, Gabrani R. Prakash V, et al. Cardiovasc Hematol Agents Med Chem. 2024;22(3):336-347. doi: 10.2174/0118715257262003231031171910. Cardiovasc Hematol Agents Med Chem. 2024. PMID: 37957904 Review.
Despite intense research in the field of glioblastoma multiforme (GBM) therapeutics, the resistance against approved therapy remains an issue of concern. ...The phytocompounds comprised in these classes are extracted or processed from certain plant sources. They can …
Despite intense research in the field of glioblastoma multiforme (GBM) therapeutics, the resistance against approved therapy r …
Ginsenoside Rg5 inhibits glioblastoma by activating ferroptosis via NR3C1/HSPB1/NCOA4.
Zhang G, Hu J, Li A, Zhang H, Guo Z, Li X, You Z, Wang Y, Jing Z. Zhang G, et al. Phytomedicine. 2024 Jul;129:155631. doi: 10.1016/j.phymed.2024.155631. Epub 2024 Apr 12. Phytomedicine. 2024. PMID: 38640858
RESULTS: To elucidate the precise molecular targets affected by ginsenoside Rg5 in gliomas, we conducted an intersection analysis between differentially expressed genes obtained from sequencing and a database-predicted list of transcription factors and potential …
RESULTS: To elucidate the precise molecular targets affected by ginsenoside Rg5 in gliomas, we conducted an intersection analy …
Engineered RAP-anchored copper-escorting liposomes for FDX1-targeted cuproptosis in glioblastoma therapy .
Liu MM, Zhao LX, Gong ZQ, He YJ, Jiang X, Luo W, Yu X, Wang ZY. Liu MM, et al. Theranostics. 2025 Jul 2;15(15):7802-7819. doi: 10.7150/thno.115723. eCollection 2025. Theranostics. 2025. PMID: 40756352 Free PMC article.
RNA sequencing was used to identify cuproptosis-related molecular targets, among which ferredoxin-1 (FDX1) was the primary focus of the study. Western blot, immunohistochemistry, immunofluorescence, flow cytometry and biochemical kits were applied to elucidate the …
RNA sequencing was used to identify cuproptosis-related molecular targets, among which ferredoxin-1 (FDX1) was the primary foc …
Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.
Videla-Richardson GA, Morris-Hanon O, Torres NI, Esquivel MI, Vera MB, Ripari LB, Croci DO, Sevlever GE, Rabinovich GA. Videla-Richardson GA, et al. Int J Mol Sci. 2021 Dec 28;23(1):316. doi: 10.3390/ijms23010316. Int J Mol Sci. 2021. PMID: 35008740 Free PMC article. Review.
Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the adult population, urging identification of new rational therapeutic targets. ...Particularly in GBM, galectins control tumor cell tran …
Despite recent advances in diagnosis and treatment, glioblastoma (GBM) represents the most common and aggressive brain tumor in the a …
Immunotherapy and targeted therapy for high grade gliomas: current and future directions.
Hsueh B, Steuart SJ, Odukoya AO, Prager BC, Kim YJ, Hill CM, Choi BD, Dunn GP. Hsueh B, et al. J Neurooncol. 2025 Dec 9;176(1):112. doi: 10.1007/s11060-025-05315-3. J Neurooncol. 2025. PMID: 41366148 Review.
METHODS: Here, we review ongoing work in the clinical development of new therapeutic strategies for high grade gliomas, discuss ongoing challenges, and highlight emerging opportunities for targeted intervention, with particular focus on molecularly targeted a …
METHODS: Here, we review ongoing work in the clinical development of new therapeutic strategies for high grade gliomas, discuss ongoing chal …
The dopamine receptor D1 inhibitor, SKF83566, suppresses GBM stemness and invasion through the DRD1-c-Myc-UHRF1 interactions.
Xue Z, Zhang Y, Zhao R, Liu X, Grützmann K, Klink B, Zhang X, Wang S, Zhao W, Sun Y, Han M, Wang X, Hu Y, Liu X, Yang N, Qiu C, Li W, Huang B, Li X, Bjerkvig R, Wang J, Zhou W. Xue Z, et al. J Exp Clin Cancer Res. 2024 Jan 22;43(1):25. doi: 10.1186/s13046-024-02947-7. J Exp Clin Cancer Res. 2024. PMID: 38246990 Free PMC article.
Knockdown and overexpression experiments were performed to find molecular pathways responsible for the therapeutic effects of SKF83566. Finally, the effects of SKF83566 were validated in orthotopic xenograft models in vivo. ...Using CMap analysis, SKF83566 was ident …
Knockdown and overexpression experiments were performed to find molecular pathways responsible for the therapeutic effects of …
76 results